Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV.

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES Global & Regional Health Technology Assessment Pub Date : 2024-12-10 eCollection Date: 2024-01-01 DOI:10.33393/grhta.2024.3167
Andrea Marcellusi, Chiara Bini, Francesco Saverio Mennini, Silvia Ripoli, Laura Fioravanti, Victoria Federico Paly, Alexa Lina Molinari, Paolo Morelli, Stanimira Krotneva, Shujun Li
{"title":"Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV.","authors":"Andrea Marcellusi, Chiara Bini, Francesco Saverio Mennini, Silvia Ripoli, Laura Fioravanti, Victoria Federico Paly, Alexa Lina Molinari, Paolo Morelli, Stanimira Krotneva, Shujun Li","doi":"10.33393/grhta.2024.3167","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"248-257"},"PeriodicalIF":0.4000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2024.3167","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Global & Regional Health Technology Assessment
Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-
CiteScore
0.80
自引率
20.00%
发文量
27
审稿时长
8 weeks
期刊介绍: Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.
期刊最新文献
Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV. A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy. Impatto economico di dapagliflozin nella gestione della malattia renale cronica in Italia: risultati di un modello di micro-simulazione. Modello predittivo di policy per una migliore gestione della broncopneumopatia cronica ostruttiva: implicazioni economico-organizzative nel contesto sanitario italiano. A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1